Objectives: Leishmaniasis, one of the most significant neglected diseases around the world, is caused by protozoan parasites of the Leishmania genus. Nowadays, the available aetiological treatments for leishmaniasis have variable effectiveness and several problems such as serious side effects, toxicity, high cost and an increasing number of resistance cases. Thus, there is an urgent need for safe, oral and cost-effective drugs for leishmaniases. Previously, our group has shown the effect of the ergosterol biosynthesis inhibitors on Leishmania amazonensis. Herein, we showed the effect of ravuconazole against L. amazonensis; ravuconazole is a second-generation triazole antifungal drug that has good bioavailability after oral administration and a long terminal half-life in humans, a broad activity spectrum, high effectiveness in treatment of mycosis and negligible side effects.
Introduction
Leishmaniasis is a neglected disease, distributed throughout the world, caused by protozoan parasites of the Leishmania genus. It is prevalent in 98 countries, with a total of 350 million people at risk and 12 million cases of infection every year. 1 The leishmaniases have been divided into three main clinical manifestations: cutaneous, mucocutaneous and visceral. 2, 3 Brazil is one of the most significant countries in its epidemiology. 1 For several years, pentavalent antimonials have been used as first-line treatment, 4 with the exception of India, 5 where the number of resistance cases has increased significantly. The second-line treatment is based on the use of amphotericin B or pentamidine, which are toxic and expensive. 6 Moreover, they have several limitations, such as serious adverse effects, high cost and cases of resistance. 7 In 2002, miltefosine was registered as the first oral treatment for visceral leishmaniasis in India; 5 however, nowadays, liposomal amphotericin B is the first-line treatment in Asia, Africa and Europe, as recommended by the WHO. 7, 8 Although miltefosine displays good efficacy, it is teratogenic, hepatotoxic and nephrotoxic. 9 Thus, there is an urgent need to identify Cell viability and cytotoxicity were evaluated against promastigotes using the MTS/PMS reaction after 48 h of treatment. The CC 50 value was 3.09 lM ravuconazole. (c) Evaluation of plasma membrane integrity of L. amazonensis promastigotes with 7-AAD after 48 h of treatment with ravuconazole. There was a significant increase in the fluorescence intensity at concentrations higher than 1 lM ravuconazole. This increase represents a decrease in viability of the treated cells. Bars represent standard deviation. *P,0.05, **P,0.01 and ***P,0.001.
Antileishmanial activity of ravuconazole JAC new therapeutic alternatives, since the current treatments are unsatisfactory.
Members of the Trypanosomatidae family such as Leishmania have a strict requirement for ergosterol and other 24-alkyl sterols that are essential for the maintenance of cell membrane structure and function and are absent in mammalian cells. 10 Several studies have shown that the sterol biosynthesis pathway might be an important druggable target in Leishmania parasites. [10] [11] [12] Azoles are a well-known class of antifungal agents that inhibit the conversion of lanosterol to zymosterol by the cytochrome P450-containing monooxygenase lanosterol C14a-demethylase. 10, 13 Some azoles have been described to be active against different Leishmania spp., such as ketoconazole, fluconazole, itraconazole and posaconazole. 8 Furthermore, our group showed the potent effect of itraconazole and posaconazole against Leishmania amazonensis alone or in combination with E5700, a known squalene synthase inhibitor, another essential enzyme in the sterol biosynthesis pathway. 14, 15 Ravuconazole (Eisai Co. Ltd, Japan) is a second-generation triazole antifungal drug that has potent activity against Trypanosoma cruzi in vitro, but its curative activity in murine and canine models of acute Chagas' disease is limited by the relatively short terminal half-life of the drug in these animal models. [16] [17] [18] Ravuconazole has a much longer half-life in humans (.120 h), offering the opportunity to assess the drug as chemotherapy for human Chagas' disease. 17, 19 The drug has good bioavailability after oral administration, particularly in its prodrug formulation (E1224, fosravuconazole 19 ), a broad activity spectrum, high effectiveness in the treatment of deep-seated mycosis and a very good safety profile. Its absorption, distribution, metabolism and excretion (ADME) profile is similar to that of posaconazole owing to its lipophilicity, which is an important feature for membrane permeability and large volumes of distribution. 20, 21 In this work, we showed the potent effect of ravuconazole in vitro against L. amazonensis promastigotes and intracellular amastigotes, inhibiting growth and inducing several alterations in morphology, ultrastructure, sterol composition and physiology of the parasite.
Materials and methods

Leishmania cultures
The MHOM/BR/75/Josefa strain of L. amazonensis (provided by the Leishmania Collection of the Instituto Oswaldo Cruz) was used in this study and it has been maintained by inoculation into the base of BALB/c mice tails. Amastigotes were obtained from mice and transformed into promastigotes that were axenically cultured in Warren's medium 22 supplemented with 10% FBS at 25 C.
was provided by Eisai Co. Ltd, dissolved in DMSO as a 10 mM stock solution and stored at #20 C. New dilutions were prepared in culture medium during the experiments, but the DMSO concentration did not exceed 0.1%.
In vitro antiproliferative effects of ravuconazole
Promastigote cultures were initiated at a cell density of 1.0%10 6 cells/mL. After 24 h of growth, ravuconazole was added at different concentrations from the stock solution. Cell densities were determined every day in a Neubauer chamber during 96 h of growth. The effects of ravuconazole on L. amazonensis intracellular amastigotes were also evaluated following experimental protocols previously published. 14, 15 The IC 50 was calculated for promastigotes and intracellular amastigotes by fitting the values to a non-linear curve analysis. The regression analyses were performed with SigmaPlot 10 software.
Cell viability assays in murine macrophages and L. amazonensis promastigotes
The CellTiter 96 V R AQueous MTS Assay (Promega) was used to evaluate the cytotoxicity effects of ravuconazole in mammal cells and the cell viability of the L. amazonensis promastigotes. MTS/PMS is a colorimetric method used to evaluate the number of viable cells in proliferation, where MTS is 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium and PMS is phenazine methosulphate. 23 Murine macrophages 15 were treated daily with different concentrations of ravuconazole for 72 h. Promastigotes of L. amazonensis were cultivated at a cell density of 1.0%10 6 cells/mL and, after 24 h of growth, ravuconazole was added at different concentrations. The cell viability was measured after 48 and 72 h of treatment in 96-well plates in triplicate. Either macrophages or promastigotes were evaluated by MTS/PMS assay reaction according to the Antileishmanial activity of ravuconazole JAC protocol published previously. 23 The CC 50 for viable macrophages and promastigotes was determined by non-linear regression using SigmaPlot software.
Electron microscopy
Control and treated promastigotes and intracellular amastigotes were fixed for at least 2 h in 2.5% glutaraldehyde (Sigma) in 0.1 M cacodylate buffer (pH 7.2) and post-fixed in a solution containing 1% OsO 4 , 1.25% potassium ferrocyanide, 5 mM CaCl 2 and 0.1 M cacodylate buffer (pH 7.2) for 30 min. Experimental protocols for scanning and transmission electron microscopy were published previously. 15 Ultrathin sections were observed under a Zeiss 900 electron microscope.
Immunofluorescence assays
Promastigotes of L. amazonensis, untreated and treated with different concentrations of ravuconazole, were washed twice with PBS (pH 7.2), fixed with 4% freshly prepared formaldehyde for 30 min and placed onto poly-L-lysine-coated coverslips to adhere. Thereafter, experimental protocols previously published by our group were used here for a-tubulin labelling. 24 Samples were observed using a Leica TCS SPE confocal microscope.
Estimation of mitochondrial transmembrane electric potential (Dw m )
Dw m of the untreated and treated promastigotes was analysed using the JC-1 fluorochrome (Molecular Probes), a lipophilic Teixeira de Macedo Silva et al.
and cationic mitochondrial vital dye that accumulates in the mitochondria in response to Dw m . 24, 25 Parasites and experimental conditions were prepared as previously described. 14, 15, 25 The experiments were repeated at least three times in triplicate and Figure 7 (a) shows the mean and standard deviation of one representative experiment.
Quantification of intracellular ATP
Intracellular ATP levels were measured using a bioluminescence assay based on the reaction catalysed by luciferase, in which its substrate D-luciferin is metabolized in the presence of ATP resulting in light that is measured at the maximum emission wavelength of 560 nm. Firstly, a standard curve of ATP concentrations was obtained, varying the ATP concentration from 1 to 100 nM; samples were analysed in a luminometer measuring the luminescence. After that, 1%10 7 parasites (untreated and treated with ravuconazole) were harvested, washed in PBS (pH 7.2), resuspended in 1 mL of boiling water using a vortex mixer and then incubated at 4 C. The amount of ATP in the supernatant was measured using the ATP Determination Kit in a luminometer (PerkinElmer) at the maximum emission wavelength of 560 nm. Experiments were repeated at least three times in triplicate and Figure 7 (b) shows the mean and standard deviation of one representative experiment.
Measurements of reactive oxygen species and mitochondrial superoxide
Reactive oxygen species (ROS) and mitochondrial superoxide were measured using two different techniques: (i) incubation with H 2 DCFDA (Molecular Probes), a non-fluorescent cell-permeant 2 0 ,7 0 -dichlorodihydrofluorescein diacetate that can be converted to a fluorescent 2 0 ,7 0 -dichlorodihydrofluorescein by intracellular esterases and oxidation in the presence of high amounts of ROS; and (ii) incubation with MitoSOX Red indicator (Molecular Probes), which is a fluorogenic dye for highly selective detection of mitochondrial superoxide in live cells. In the mitochondrion, MitoSOX Red is oxidized exclusively by superoxide with emission fluorescence at 580 nm (red channel). For the analyses, 3%10 7 cells were prepared according to previous work. 15 Experiments were repeated at least three times in triplicate and Figure 7 (c-d) shows the mean and standard deviation of one representative experiment.
Evaluation of plasma membrane integrity
Plasma membrane integrity was evaluated using the fluorescent intercalator 7-aminoactinomycin D (7-AAD), which is excluded from live cells and undergoes a spectral shift upon association with DNA. Control and treated promastigotes were washed in PBS (pH 7.2) and resuspended in a volume of 500 lL. After that, 2 lg/mL 7-AAD (Molecular Probes) was added and samples Antileishmanial activity of ravuconazole JAC were incubated for 15 min at 25 C, protected from light. For this analysis, a positive control with 0.1% Triton X-100 (Sigma) was used. Samples were then analysed by flow cytometry (BD Accuri C6) using an argon-ion laser for excitation at 488 nm and the maximum emission was measured at 647 nm. Experiments were repeated at least three times in triplicate and Figure 1(c) shows the mean and standard deviation of one representative experiment.
Neutral lipid accumulation
Presence of lipid bodies was evaluated by incubating parasites with Nile red, a fluorescence marker for neutral lipid. For that, 1.0%10 7 promastigotes were harvested, washed in PBS (pH 7.2) and incubated with 10 lg/mL Nile red (Sigma) for 20 min. After that, cells were washed twice, resuspended in 200 lL of PBS and then added to a black 96-well plate. The experiments were performed in triplicate and samples were read in a microplate reader and spectrofluorimeter SpectraMax M2/M2e at 485 and 538 nm wavelengths for excitation and emission, respectively. After readings, control and treated parasites were fixed with 4% nascent formaldehyde in 0.1 M phosphate buffer (pH 7.2) and observed using a Leica DMI 6000 microscope.
Extraction, separation of neutral lipids and free sterol analysis
For the analysis of the effects of ravuconazole on the free sterol composition of the promastigotes, total lipids were extracted from control and drug-treated L. amazonensis promastigotes, as Teixeira de Macedo Silva et al.
described previously. 26, 27 Neutral lipids were analysed by MS and mass spectra were obtained by electron ionization (EI) at 70 eV according to the protocol published previously. 26, 27 The assignment of structures was based on relative chromatographic behaviours as well as the characteristic fragmentation patterns in MS and by comparison of the mass spectra with those available in the National Institute of Standards and Technology (NIST) Research Library located at the NIST Mass Spectrometry Data Center.
Ethics
All animal models used were approved by the Ethics Committee 
Statistical analyses
Statistical significance of differences among the groups was assessed using the one-way analysis of variance (ANOVA) test followed by Bonferroni's multiple comparison test in GraphPad Prism 4 Software. Graphics were made using the mean of three independent experiments, where bars represent the standard deviation between them. Results were considered statistically significant when P , 0.05.
Results
Ravuconazole induced growth inhibition of L. amazonensis with low cytotoxicity to mammal cells Figure 1 shows the antiproliferative effect of ravuconazole on the proliferation of L. amazonensis promastigotes and intracellular amastigotes. Ravuconazole had significant activity against promastigotes resulting in a concentration-dependent effect on growth inhibition and an IC 50 value of 0.87 lM after 48 h of treatment ( Figure 1a and Table 1 ). In addition, analysis of cell viability using the MTS/PMS assay and 7-AAD indicated that ravuconazole is lytic for promastigotes at concentrations above 0.5 lM (Figure 1b  and c) . As is characteristic of the effects of ergosterol biosynthesis inhibitors (EBIs) on Leishmania spp. and other susceptible organisms, 14-16 a delayed lytic effect was observed; at 48 h of exposure to 0.5 lM of the drug, complete growth arrest and loss of cell viability ensued, which is associated with the depletion of essential C-24 alkyl sterols (Table 2 ).
Ravuconazole was also tested against L. amazonensis intracellular amastigotes, presenting IC 50 values of 5.11 and 1.65 lM after 48 and 72 h of treatment, respectively (Figure 2a) . We also evaluated the cytotoxic effects of treatment with ravuconazole on murine macrophages using the MTS/PMS assay and CC 50 values of 70 and 47.68 lM were observed for 48 and 72 h of treatment, respectively (Figure 2b and c) . Thus, the selectivity index obtained was 28.9 after 72 h of treatment. IC 90 values for both promastigotes and intracellular amastigotes were around 8-10 lM (Table 1) . Antileishmanial activity of ravuconazole
JAC
Ravuconazole altered the morphology of the promastigotes followed by changes in the cytoskeleton Scanning electron microscopy revealed profound alterations in the morphology of promastigotes after treatment with ravuconazole for 48 h (Figure 3b-f ). Promastigotes treated with 0.5 lM ravuconazole appeared rounded and swollen (Figure 3b and d) . Interestingly, at different concentrations the cell surface of promastigotes became crumpled (Figure 3c , e and f). Alterations in the shape of promastigotes were also observed by differential interference contrast (DIC) microscopy when promastigotes were treated with 3 and 5 lM ravuconazole (Figure 4) . Changes in the tubulin labelling for subpellicular microtubules were observed after treatment; fluorescence images revealed the formation of large tubulin clusters (white arrowheads) in treated parasites (Figure 4) . Incubation with Hoechst to label the nucleus and kinetoplast showed that ravuconazole did not interfere with the cell cycle, a result that was corroborated by flow cytometry analysis of propidium iodide labelling (data not shown). Antileishmanial activity of ravuconazole
Ravuconazole altered mitochondrial ultrastructure and function
Transmission electron microscopy was used to study the ultrastructure of treated Leishmania to identify the main organelles affected by ravuconazole. Figure 5 (a) shows a control L. amazonensis promastigote presenting a normal ultrastructure for organelles such as the mitochondrion and nucleus. The mitochondrion was the organelle most altered by the drug treatment (Figure 5b-f) , appearing swollen and completely disorganized. Some images also suggested a close association between autophagosomes and mitochondria ( Figure 5c, d and f) . Similar alterations were observed in intracellular amastigotes (Figure 6 ), in which the mitochondrion appeared swollen (Figure 6c ). In addition, Figure 6 (d) indicates loss of the mitochondrial matrix content and the presence of a giant autophagosome near the mitochondrion. Since the mitochondrion ultrastructure was significantly altered in treated cells, we decided to analyse mitochondrial function using four criteria: Dw m using JC-1 fluorochrome; measurement of ATP levels; production of ROS; and production of superoxide radicals. Promastigotes were treated with ravuconazole and then analysed to evaluate Dw m in parallel with measurements of ATP production. The pre-treatment with ravuconazole for 48 h led to a marked reduction of Dw m , similar to that observed with Carbonyl cyanide 4-(trifluoro-methoxyl)phenylhydrazone (FCCP), a classical protonophore that abolishes Dw m (Figure 7a ). The decrease in Dw m was associated with a reduction in intracellular ATP levels after treatment with 0.5, 3 and 5 lM ravuconazole (Figure 7b ). We also analysed the effect of ravuconazole on ROS and mitochondrial superoxide production in treated promastigotes; we used amiodarone as a positive control, owing to its known inhibitory activity on oxidative phosphorylation via dissipation of Dw m and increase in ROS and superoxide production. 15, 25 Treatment with ravuconazole induced an increase in ROS; the effect was most evident with 1, 3 and 5 lM (Figure 7c) . Furthermore, all treatments also induced a significant increase in mitochondrial superoxide production (Figure 7d) . These results indicated a potent deleterious effect of ravuconazole on the mitochondrial physiology of promastigotes, consistent with the results obtained by transmission electron microscopy.
Ravuconazole induced the accumulation of lipid bodies
Untreated and treated promastigotes were incubated with Nile red, a phenoxazone dye that binds to neutral lipids and can be used for quantification of lipid bodies.
10,14 Fluorescence Teixeira de Macedo Silva et al.
microscopy revealed the presence of lipid bodies randomly distributed throughout the cytoplasm in both untreated and treated promastigotes ( Figure 8) ; however, in treated parasites there was a time-dependent increase in these structures (Figure 8e-h) , not seen in control cells (Figure 8c and d) . Quantitative fluorimetric analysis revealed that all treatments induced accumulation of lipid bodies after 48 h of treatment (Figure 8a and b) , which was not observed in control cells. Lipid bodies were also observed by transmission electron microscopy in promastigotes (Figure 5e ) and intracellular amastigotes (Figure 6b and c) .
Effects of ravuconazole on L. amazonensis free sterol composition
High-resolution capillary GC coupled with MS was used to analyse the free sterol composition of control and treated promastigotes ( Table 2 ). The free sterols of control (untreated) promastigotes were ergosta-5,7,24(24 0 )-trien-3b-ol (5-dehydroepisterol) and ergosta-7,24(24 0 )-dien-3b-ol (episterol), both synthesized de novo, which accounted for 76% and 13%, respectively, of the total sterols, while cholesterol, taken by endocytosis from the growth medium, accounted for 11%. When promastigotes were exposed to ravuconazole for 72 h it was found that the concentrationdependent effect on the growth rate of these cells (Figure 1 ) was associated with marked changes in their sterol content (Table 2) : (i) a dramatic reduction of the major sterols, 5-dehydroepisterol and episterol, found in control cells; and (ii) a concomitant accumulation of endogenous 14-methyl-sterols, mainly 14a-methylergosta-8,24(24 0 )-dien-3b-ol and 4a,14a-dimethyl-ergosta-8,24(24 0 )-dien-3b-ol (obtusifoliol), which accounted for 82%-87% of total free sterols at the concentrations assessed, whereas cholesterol levels remained constant, at 7%-10%. These results are essentially identical to those observed in our previous study on the effects of itraconazole and posaconazole on this parasite 15 and indicated that the primary target of ravuconazole in L. amazonensis promastigotes is the cytochrome P450-dependent sterol C14a demethylase, as expected.
Discussion
Although leishmaniasis has a high socio-economic impact worldwide, there is no commercial interest in developing new pharmaceutical compounds. Nowadays, the treatments available result in several complications for the patients. 9, 12, 28 We have focused the present and previous studies on L. amazonensis as in Brazil it is one of the most significant species that can cause all clinical manifestations of leishmaniasis; 29 also, it is particularly important for the epidemiology of leishmaniasis in the Amazon region. 30 When the immune system fails to mount an appropriate response against the parasite it can lead to diffuse cutaneous leishmaniasis, which is a serious public health problem in Brazil because the lesions cover a large part of the body, with devastating effects on the patients, and it is incurable using currently available treatments. 30, 31 Thus, there is an urgent need for development of new chemical entities that could be used for treatment of leishmaniasis. One of the interesting tools in medicinal chemistry is drug transposition, in which molecules with known activity for related diseases are tested for neglected diseases. From this perspective, azole derivatives, which are known inhibitors of sterol C14a-demethylase and used for the treatment of fungal infections, have been tested against protozoan parasites such as Leishmania spp. and our previous studies have shown that L. amazonensis is particularly susceptible to such inhibitors. 14, 15, 32, 33 Ravuconazole is a second-generation triazole that has been developed for the treatment of invasive fungal infections. 34 Against intracellular amastigote forms of Trypanosoma cruzi, ravuconazole showed potent activity in vitro with an MIC of 1 nM after 96 h of treatment. 16 In animal models of Chagas' disease the anti-T. cruzi activity of ravuconazole was limited by the short serum half-life of the drug in mice and dogs, 16, 17 but the much longer half-life in humans suggests that ravuconazole should be efficacious for treatment of human Chagas' disease, with appropriate doses and treatment duration. 17, 19 In the present study, we found a potent in vitro effect of ravuconazole against promastigotes and intracellular amastigotes of L. amazonensis. Comparing the effects on intracellular amastigotes, the activity of the drug against L. amazonensis was lower than that against T. cruzi, as the IC 50 value found in our study after 72 h of treatment (1.65 lM) was significantly higher than that for T. cruzi. 16 For L. amazonensis, itraconazole was more potent than ravuconazole against promastigotes after 72 h of treatment, 14 but ravuconazole had better activity than posaconazole after the same incubation time; however, for intracellular amastigotes, the IC 50 values were similar. 14 We also evaluated the viability of promastigotes by different methods to investigate the cellular mechanism of action of ravuconazole. Using the MTS/PMS metabolic assay and the fluorescent marker 7-AAD for DNA we found that ravuconazole affected the shape, plasma membrane integrity and cell viability after 72 h of incubation at .0.5 lM. GC-MS analysis showed that the alterations mentioned above were associated with drastic changes in the composition of parasite sterols as the main sterols (episterol and 5-dehydroepiserol) were almost completely replaced by 14a-methyl sterols. Thus, alterations in the lipid composition of the plasma membrane seem to result in significant changes in its permeability properties, leading to cell death of the parasites by a mechanism similar to necrosis in human cells. Moreover, when the parasites were treated with the same levels of ravuconazole, Dw m decreased significantly, resulting in a reduction of intracellular ATP levels and an increase in mitochondrial ROS production ( Figure 7) . Consistently, transmission electron microscopy images indicated that the mitochondrion ultrastructure was dramatically altered in both developmental stages of the parasite (Figures 5 and 6 ). We also observed some structures similar to autophagic vacuoles close to mitochondria, indicating a possible induction of the mitophagy process. Several studies from our group showed the effects of EBIs on the L. amazonensis and T. cruzi mitochondrion. 14, 15, 25, 26, 35 As published previously, the single mitochondrion of trypanosomatids has a special sterol composition, 36 confirming that this organelle is a primary target for EBIs. The mitochondrion alterations were accompanied by accumulation of lipid bodies in the cytoplasm of the parasites (Figure 8 ). Several studies had reported these lipid bodies as a place of abnormal accumulation of endogenous intermediates, most probably resulting from the inhibition of ergosterol biosynthesis. 26 In conclusion, ravuconazole has potent antiproliferative effects on promastigotes and intracellular amastigotes of L. amazonensis. Ravuconazole is able to alter the composition of free sterols, Antileishmanial activity of ravuconazole JAC physiology, morphology and ultrastructure of promastigotes, leading to cell lysis. Together, these results indicate that ravuconazole could be a promising treatment for leishmaniasis, alone or in combination with other drugs, and support future in vivo studies in murine models infected with L. amazonensis.
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